Investigation for the effect of anti-dyslipidemic drugs on serum level of trans-fatty acids

Investigation for the effect of anti-dyslipidemic drugs on serum level of trans-fatty acids - Trans-fat level-reducing drug study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000026984

Enrollment

Registered

2018-03-31

Start date

2016-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

dyslipidemia

Interventions

Purified EPA 1800mg/day 14 days ezetimibe 10mg/day 14 days

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Healthy volunteer

Exclusion criteria

Exclusion criteria: 1. Lack of informed consent 2. Pregnancy 3. Allergy against ezetimibe or EPA

Design outcomes

Primary

Measure	Time frame
Serum trans-fatty acid concentration and lipid profile after 2 weeks of anti-dyslipidemic drugs.	—

Countries

Japan

Contacts

Public ContactTatsuro Ishida

Kobe University Graduate School of Medicine Division of Cardiovascular Medicine

ishida@med.kobe-u.ac.jp078-382-5846

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026